Ani Pharmaceuticals Inc. (anip 2.25 09/01/29)
13F holders, Q2 2026 (June 30)3holders −1
0new positions
1sold out
$2.67avg. 13F price*
At the end of Q2 2026, 3 institutions reported holding Ani Pharmaceuticals Inc. (anip 2.25 09/01/29) in their 13F filings, down 1 from Q1 2026. 0 opened new positions and 1 sold out. The largest holders were Boussard & Gavaudan Gestion Sas ($17.1M), Absolute Investment Advisers, LLC ($15.2M) and Bank of New York Mellon Corp ($845K).
- Company
- Ani Pharmaceuticals Inc. (anip 2.25 09/01/29)
- CUSIP
- 00182CAC7
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $18.6M |
All 13F filers, Q1 2026 → Q2 2026: 250,000 shares bought and 15,350,000 shares sold, net −15,100,000 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Boussard & Gavaudan Gestion Sas | 2.08% | — | 13,000 | $17.1M |
| Absolute Investment Advisers, LLC | 1.47% | Add +2.2% | 11,723,000 | $15.2M |
| Bank of New York Mellon Corp | 0.00% | Reduce -35.0% | 650,000 | $845K |
"% of holder's portfolio" is ANI PHARMACEUTICALS INC (ANIP 2.25 09/01/29)'s weight in each manager's 13F, not the share of Ani Pharmaceuticals Inc. (anip 2.25 09/01/29) the manager owns.